FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of TNBC By Ogkologos - August 5, 2026 48 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ASCENT-03 and ASCENT-04/KEYNOTE D-19 studies Source RELATED ARTICLESMORE FROM AUTHOR New Translations of the ESMO Patient Guides Available in Estonian Trend in Survival Benefit with a Combination of Spartalizumab Plus Dabrafenib and Trametinib Over Targeted Therapy Alone for BRAF V600-mutated Metastatic Melanoma FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase alfa-pmph Each with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer MOST POPULAR FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial... July 23, 2021 Use of Immune Checkpoint Inhibitors is Safe and Effective in Patients... May 26, 2023 When You Have Cancer and You’re a Parent: “Your Stories” Podcast February 17, 2021 New study supports extending cervical screening intervals for people who test... May 31, 2022 Load more HOT NEWS The US National COVID Cohort Collaborative Consortium Provides Real-World Evidence on... Same Breast Cancer, Same Place, Same Treatment. This Mother and Daughter... Nivolumab/Ipilimumab Combination Should Precede Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated... FDA Approves Pralsetinib for RET-Altered Thyroid Cancers
